Vilon (Lys-Glu or KE) is one of the most studied Khavinson bioregulatory peptides, developed at the Saint Petersburg Institute of Bioregulation and Gerontology. Professor Vladimir Khavinson has spent over 40 years researching short peptides (2-4 amino acids) that regulate gene expression in specific tissue types. Vilon is classified as an immunomodulatory bioregulator — a dipeptide consisting of lysine and glutamic acid that targets immune system tissues. Research suggests these short peptides can penetrate the cell nucleus and interact with specific DNA sequences, modulating gene expression related to cell differentiation, proliferation, and apoptosis. Vilon has been shown to restore thymic function in aging organisms, promote T-cell differentiation, and enhance immune surveillance. It has been used in Russian medical practice for decades and represents the growing field of peptide bioregulation, which proposes that short peptides serve as natural gene regulators that can be supplemented to counteract age-related functional decline.
Key Data
Mechanism of Action
Vilon acts as a bioregulator by interacting with DNA and modulating gene expression in immunocompetent cells. It promotes differentiation of immune progenitor cells and enhances thymic function. As a short peptide, it can penetrate cell membranes and interact directly with chromatin.
Reported Benefits
All information is presented for Research Use Only (RUO). Not medical advice.